Macrophage activation syndrome and post-transplant microangiopathy following haploidentical bone marrow transplantation for sickle cell anemia

Am J Hematol. 2018 Aug;93(4):588-589. doi: 10.1002/ajh.24995. Epub 2017 Dec 18.

Authors

James O J Davies¹, Alice C Hart¹, Josu De La Fuente^{1

2}, Barbara J Bain^{1

2}

Affiliations

¹ St Mary's Hospital, Imperial College Healthcare NHS Foundation Trust, Praed Street, London, W2 1NY, United Kingdom.
² St Mary's Hospital Campus, Imperial College London Faculty of Medicine, St Mary's Hospital, London, W2 1NY, United Kingdom.

PMID: 29197110
DOI: 10.1002/ajh.24995

No abstract available

Publication types

Case Reports

MeSH terms

Adolescent
Anemia, Sickle Cell / therapy*
Antibodies, Monoclonal, Humanized / therapeutic use
Bone Marrow Transplantation / adverse effects*
Cyclophosphamide / adverse effects
Cyclophosphamide / therapeutic use
Cytokines / therapeutic use
Erythrocytes, Abnormal / ultrastructure
Febrile Neutropenia / chemically induced
Female
Graft vs Host Disease / prevention & control
Herpesvirus 6, Human / isolation & purification
Humans
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use
Macrophage Activation Syndrome / etiology*
Mesenchymal Stem Cell Transplantation
Monocytes / ultrastructure
Plasma Exchange
Rituximab / therapeutic use
Roseolovirus Infections / complications
Thrombotic Microangiopathies / blood
Thrombotic Microangiopathies / etiology*
Thrombotic Microangiopathies / immunology
Thrombotic Microangiopathies / therapy
Transplantation Conditioning / adverse effects

Substances

Antibodies, Monoclonal, Humanized
Cytokines
Immunosuppressive Agents
Rituximab
Cyclophosphamide
eculizumab